Amplified Sciences initiated patient enrollment for PanAMP, a multicenter real-world clinical utility study evaluating its PanCystPro assay’s effect on clinical decision-making for early pancreatic cancer detection. The company is assessing whether test results change real-world pathways such as follow-on testing, referrals, and patient management. PanAMP is designed as a clinical utility study rather than a traditional efficacy endpoint trial, reflecting an increasing push for evidence around how diagnostics are used in practice. The enrollment start adds momentum for PanCystPro as the company looks to demonstrate not only detection performance but also practical adoption in routine care settings across multiple centers.